AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Invion (ASX:IVX) is developing a novel next-generation PDT against cancer, atherosclerosis, and infectious diseases
- Invion’s lead cancer drug candidate is INV043, which has demonstrated encouraging results in proof-of-concept studies
- An in vitro study indicated INV043’s effectiveness against six SCC cell lines linked to anal cancer
- As per Invion’s reference to market studies, the global anal cancer treatment market is forecast to grow at a CAGR of 6.3% by 2028.
Invion Limited (ASX:IVX) is steered by its mission of transforming Photodynamic Therapy (PDT) to treat cancer effectively. The company is at the forefront of the global research and development of Photosoft™ technology, a novel next-generation PDT.
© 2022 Kalkine Media®, Data source: Company update
Invion is working towards developing Photosoft™ technology against cancer, atherosclerosis, and infectious diseases. Cancer is the company's primary focus, and it is preparing to start Phase I clinical trials across multiple cancer indications in 2023. The company is advancing multiple programs in partnership with the Hudson Institute of Medical Research and the Peter MacCallum Cancer Centre.
Invion’s lead cancer drug candidate is INV043, which has demonstrated encouraging results in proof-of-concept studies. Currently, the company is progressing studies focused on various cancers including anal cancer and triple negative breast cancer.
© 2022 Kalkine Media®, Data source: Company update
How effective is Invion’s lead drug candidate against anal cancer
Anal cancer is a condition in which malignant (cancer) cells are formed in anus tissues. Most of these are related to the infection of the human papillomavirus (HPV). The most common indications of this disease are bleeding from the anus or rectum or a lump near the anus.
Promising results against anal cancer - An in vitro study showed INV043’s effectiveness against six squamous cell carcinoma (SCC) cell lines. SCC cell lines are related to anal cancer, and the tests conducted by Peter Mac demonstrated the effectiveness of photoactivated INV043 against the six SCC cell lines spanning the range found in anal cancers.
Date source: IVX update
Squamous cell carcinoma - These tumours begin in the squamous cells that line the majority of the anal canal and the anal margin. They develop in the anal canal beyond the surface and into the deeper layers of the lining.
In the United States, nearly nine out of the 10 cases of anal cancer are squamous cell cancer.
Anal cancers are mostly hard to treat, and most of the cases are SCCs that line the exterior of the anal canal.
Billion-dollar market opportunity - Referring to data from Coherent Market Insights, Invion highlights a huge opportunity in the global anal cancer market, which is projected to grow at a compound annual growth rate (CAGR) of 6.3%. The global anal cancer market is forecast to reach US$1.25 billion by 2028.
Source: IVX update, dated 15 September 2022
IVX shares were trading at AU$0.009 in the early hours of 21 December 2022.
